Steven C. Crouse, President of Diagnostics and Spatial Biology at BIO-TECHNE Corp (NASDAQ:TECH), filed a Form 4 on August 18, 2026, reporting transactions in common stock dated August 15, 2026, including the vesting of restricted stock units and a related share withholding.

Key Highlights

  • RSU conversion: 5,423 shares of common stock were acquired via an M-coded (exercise/conversion) transaction at $0 on August 15, 2026.
  • Shares withheld for tax: 1,947 shares were disposed of under transaction code F at a price of $72.4 per share on August 15, 2026.
  • Post-transaction ownership: Crouse directly owned 10,237 shares of common stock following the reported transactions.
  • Derivative holdings: Crouse holds stock options with exercise prices ranging from $48.61 to $120.46, covering a total of over 110,000 underlying shares across multiple tranches.
  • Remaining RSUs: Several restricted stock unit awards remain outstanding, including 794 units vesting on 5/1/2027 and 1,200 units vesting across 6/2/2027 and 6/2/2028.
  • Performance RSUs: 2,387 performance restricted stock units vest on or after 8/15/2028, contingent on certain performance goals being achieved.

BIO-TECHNE Officer RSU Vest and Share Withholding on August 15, 2026

According to the filing, Steven C. Crouse, identified as an officer holding the title "President - Diag & Spatial Bi" at BIO-TECHNE Corp (NASDAQ:TECH), reported two non-derivative transactions on August 15, 2026. First, 5,423 shares were acquired through the conversion of restricted stock units at $0, coded as transaction type M. Second, 1,947 shares were disposed of under transaction code F at $72.4 per share, a transaction type typically associated with shares withheld to cover tax obligations upon vesting. Following these transactions, the filing reports Crouse directly held 10,237 shares of common stock.

The filing also details the RSU conversions in Table II. Three RSU tranches were converted on August 15, 2026, specifically 1,379 units, 1,868 units, and 2,176 units, all coded M and priced at $0. After the conversions, remaining derivative positions include RSU tranches with future vesting dates, stock options with expiration dates ranging to 2036, and 2,387 performance restricted stock units that the filing states "vest in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator)."

The filing was signed by Andrew Nick as Attorney-in-Fact for Steven C. Crouse pursuant to a previously filed Power of Attorney, and was filed on August 18, 2026. Each restricted stock unit, the filing notes, "represents a contingent right to receive one share of Bio-Techne common stock."

What Was Disclosed

The filing reports the vesting and conversion of restricted stock units into 5,423 common shares, the withholding of 1,947 shares at $72.4 each, and a resulting direct ownership of 10,237 shares, along with extensive remaining derivative positions, for BIO-TECHNE officer Steven C. Crouse.